Mepenzolate bromide displays beneficial effects in a mouse model of chronic obstructive pulmonary disease

ABSTRACT: For the clinical treatment of chronic obstructive pulmonary disease (COPD), it is important not only to improve the airflow limitation by bronchodilation but also to suppress emphysema by controlling inflammation. In this study, we have screened for compounds that prevent elastase-induced airspace enlargement in mice from medicines already used clinically. Mepenzolate bromide, a muscarinic antagonist used to treat gastrointestinal disorders was selected. Intratracheal administration or inhalation of mepenzolate bromide decreased the severity of elastase-induced airspace enlargement, alteration of lung mechanics and respiratory dysfunction. While mepenzolate bromide showed bronchodilatory activity, most of other muscarinic antagonists tested did not improve the elastase-induced pulmonary

ORGANISM(S): Mus musculus

SUBMITTER: Kaoru Mogushi 

PROVIDER: E-GEOD-50836 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress